Literature DB >> 15868465

Molecular mechanism of dominant expression in 3-methylcrotonyl-CoA carboxylase deficiency.

M R Baumgartner1.   

Abstract

Most enzyme deficiencies in humans are inherited as autosomal recessive traits. The term dominant negative is applied to mutant alleles in which a mutant protein interferes in one way or another with the function of the normal protein being produced from the wild-type allele in a heterozygote. Such a dominant negative effect usually involves homomeric or heteromeric proteins. 3-Methylcrotonyl-CoA carboxylase (MCC) is a heteromeric mitochondrial enzyme comprised of biotin containing MCCalpha subunits and smaller MCCbeta subunits, encoded by the genes MCCA and MCCB, respectively. Mutations in these genes cause isolated MCC deficiency, an autosomal recessive disorder with a variable phenotype ranging from severe neonatal to asymptomatic adult forms. Patients with MCC deficiency have a characteristic organic aciduria with greatly increased excretion of 3-hydroxyisovaleric acid (3-HIVA) and 3-methylcrotonyl-glycine (3-MCG). Here, two patients with elevated excretion of 3-MCG and 3-HIVA and partial deficiency of MCC are discussed, one of them with severe neurological symptoms. Both showed evidence of biotin responsiveness and were heterozygous for the missense mutation MCCA-R385S. Evidence is presented that MCCA-R385S is a dominant negative allele leading to biochemical abnormalities and clinical symptoms in heterozygous individuals and that it is responsive to pharmacological doses of biotin in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15868465     DOI: 10.1007/s10545-005-7054-3

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  6 in total

1.  Severe hypoglycaemia in isolated 3-methylcrotonyl-CoA carboxylase deficiency; a rare, severe clinical presentation.

Authors:  H G M Oude Luttikhuis; G Touati; D Rabier; M Williams; C Jakobs; J M Saudubray
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  Inhibition of 3-methylcrotonyl-CoA carboxylase explains the increased excretion of 3-hydroxyisovaleric acid in valproate-treated patients.

Authors:  Paula B M Luís; Jos P Ruiter; Lodewijk IJlst; Luísa Diogo; Paula Garcia; Isabel Tavares de Almeida; Marinus Duran; Ronald J Wanders; Margarida F B Silva
Journal:  J Inherit Metab Dis       Date:  2011-12-22       Impact factor: 4.982

3.  Urinary excretion of 3-hydroxyisovaleric acid and 3-hydroxyisovaleryl carnitine increases in response to a leucine challenge in marginally biotin-deficient humans.

Authors:  Donald M Mock; Shawna L Stratton; Thomas D Horvath; Anna Bogusiewicz; Nell I Matthews; Cindy L Henrich; Amanda M Dawson; Horace J Spencer; Suzanne N Owen; Gunnar Boysen; Jeffery H Moran
Journal:  J Nutr       Date:  2011-09-14       Impact factor: 4.798

4.  A new mechanism of dominance in hypophosphatasia: the mutated protein can disturb the cell localization of the wild-type protein.

Authors:  A S Lia-Baldini; I Brun-Heath; C Carrion; B Simon-Bouy; J L Serre; M E Nunes; E Mornet
Journal:  Hum Genet       Date:  2008-03-14       Impact factor: 4.132

5.  Biochemical and molecular characterization of 3-Methylcrotonylglycinuria in an Italian asymptomatic girl.

Authors:  Carla Cozzolino; Guglielmo Rd Villani; Giulia Frisso; Emanuela Scolamiero; Lucia Albano; Giovanna Gallo; Roberta Romanelli; Margherita Ruoppolo
Journal:  Genet Mol Biol       Date:  2018-05-14       Impact factor: 1.771

6.  Consanguinity and rare mutations outside of MCCC genes underlie nonspecific phenotypes of MCCD.

Authors:  Peter J Shepard; Bruce A Barshop; Matthias R Baumgartner; John-Bjarne Hansen; Kristen Jepsen; Erin N Smith; Kelly A Frazer
Journal:  Genet Med       Date:  2014-11-06       Impact factor: 8.822

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.